Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Gisela Caceres"'
Autor:
Kathy L McGraw, Ashley A Basiorka, Joseph O Johnson, Justine Clark, Gisela Caceres, Eric Padron, Ruth Heaton, Yukiyasu Ozawa, Sheng Wei, Lubomir Sokol, Alan F List
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114249 (2014)
Anemia remains the principal management challenge for patients with lower risk Myelodysplastic Syndromes (MDS). Despite appropriate cytokine production and cellular receptor display, erythropoietin receptor (EpoR) signaling is impaired. We reported t
Externí odkaz:
https://doaj.org/article/5145fb13157a414caa512e88a2d364e5
Autor:
Christopher P. Venner, Joanna Wegrzyn Woltosz, Thomas J. Nevill, H. Joachim Deeg, Gisela Caceres, Uwe Platzbecker, Bart L. Scott, Lubomir Sokol, Sandy Sung, Alan F. List, Aly Karsan
Publikováno v:
Haematologica, Vol 98, Iss 3 (2013)
We examined whether lenalidomide exposure up-regulates miRNAs and mRNAs, previously shown to play a role in the disease phenotype of del(5q) myelodysplastic syndrome, in pre-treatment CD34+ marrow cells. We hypothesized that increased expression woul
Externí odkaz:
https://doaj.org/article/037dbe181834463da7611ea11427fd02
Autor:
Vincent Law, Zhihua Chen, Francesca Vena, Inna Smalley, Robert Macaulay, Brittany R Evernden, Nam Tran, Yolanda Pina, John Puskas, Gisela Caceres, Simon Bayle, Joseph Johnson, James K C Liu, Arnold Etame, Michael Vogelbaum, Paulo Rodriguez, Derek Duckett, Brian Czerniecki, Ann Chen, Keiran S M Smalley, Peter A Forsyth
Publikováno v:
Neuro-oncology. 24(10)
Background Leptomeningeal disease (LMD) occurs as a late complication of several human cancers and has no rationally designed treatment options. A major barrier to developing effective therapies for LMD is the lack of cell-based or preclinical models
Autor:
Rami S. Komrokji, Kevin Shahbazian, Wonhee So, Ana Paula Velez, Gisela Caceres, Timothy Edward Kubal, Yasmina S. Salchert, Rod Quilitz, Farnoosh Abbas-Aghababazadeh, John N. Greene, Dahui Qin, Brooke L. Fridley, Kerry Kelly, Jeffrey E. Lancet, Yanina Pasikhova, J. Kevin Hicks, Howard L. McLeod
Publikováno v:
Clin Pharmacol Ther
A risk mitigation strategy was implemented to determine if a higher prophylactic voriconazole dosage in patients with CYP2C19 rapid metabolizer neutropenic acute myeloid leukemia (AML) reduces the incidence of subtherapeutic trough concentrations. Pa
Autor:
Nam D. Tran, Keiran S.M. Smalley, Peter A. Forsyth, Nikhil I. Khushalani, Vincent Law, Yolanda Pina, Sepideh Mokhtari, John Puskas, Edwin Peguero, Gisela Caceres, Brittany Evernden, Inna Smalley
Publikováno v:
Neuro Oncol
BACKGROUND Leptomeningeal disease (LMD) is devastating with a median survival of only 8–10 weeks. LMD affects approximately 5% to 25% of melanoma patients. Its pathophysiology remains unknown and effective treatments are virtually non-existent. The
Autor:
Vincent Law, Zhihua Chen, Inna Smalley, Francesca Vena, Robert Macaulay, Brittany Evernden, Nam Tran, Ann Chen, Yolanda Pina, Gisela Caceres, John Puskas, Derek Duckett, Keiran Smalley, Peter Forsyth
Publikováno v:
Neuro-Oncology Advances. 3:iii8-iii8
Background Approximately 5% of melanoma patients (pts) will develop LMD. Currently there is no effective treatments for this disease. A significant barrier to the development of effective therapies has been the inability to culture CSF-CTCs for funct
Autor:
John Puskas, Arnold B. Etame, Keiran S.M. Smalley, Nam D. Tran, Vincent Law, Elena Ryzhova, Gisela Caceres, Anthony M. Magliocco, Peter A. Forsyth, Solmaz Sahebjam, Brittany Evernden, Inna Smalley
Publikováno v:
Neuro Oncol
BACKGROUND Approx. 5% of melanoma pts develop LMD. There are essentially no models of LMD available for therapeutic development. A significant barrier to the development of effective therapies against LMD has been the inability to culture and expand
Autor:
Arnold B. Etame, Keiran S.M. Smalley, Gisela Caceres, Anthony M. Magliocco, Solmaz Sahebjam, Peter A. Forsyth, John Puskas, Vincent Law, Elena Ryzhova, Rajappa S. Kenchappa, Brittany Evernden, Inna Smalley
Publikováno v:
Neuro-oncology Advances
BACKGROUND: Approximately 5% of melanoma pts develop LMDz. There are essentially no models of LMDz available for therapeutic development. Here we report, the in-vitro & in-vivo culturing of CSF-CTCs. METHODS: CSF-CTCs were detected by the Veridex Cel
Autor:
Shilpa Gupta, Gisela Caceres, Jingsong Zhang, Fadzai Masawi, Yulia Doronin, John Puskas, Anthony Martin Magliocco, Jasreman Dhillon
Publikováno v:
Journal of Clinical Oncology. 37:471-471
471 Background: Novel targeted therapies are an unmet need in mBC. Androgen receptor (AR) is a rational target in BC and we conducted a phase 1/1b trial assessing safety and tolerability of AR antonist, enzalutamide (ENZ) in combination with gemcitab
Autor:
F. Joseph Daugherty, Ji-Hyun Lee, Rami S. Komrokji, Alan F. List, Ling Zhang, Najla Al Ali, Gisela Caceres, William J. Fulp, Sheng Wei, Richard A. Wells, Neil Littleton, Kathy L. McGraw, Joseph O. Johnson, Jacqueline Boultwood, Andrea Pellagatti, Lubomir Sokol, Larry J. Smith, Kenian Liu, Ashley A. Basiorka, Lan Min Zhang, Bon Ham Yip
Stabilization of p53 in erythroid precursors in response to nucleosomal stress underlies the hypoplastic anemia in myelodysplastic syndromes (MDS) with chromosome 5q deletion [del(5q)]. We investigated whether cenersen, a clinically active 20-mer ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c4668418894685372253ee7e83332f
https://ora.ox.ac.uk/objects/uuid:246ea8a8-470f-4543-9b1a-da60e1dfea0b
https://ora.ox.ac.uk/objects/uuid:246ea8a8-470f-4543-9b1a-da60e1dfea0b